搜索临床试验以:伊马替尼 (STI571)
总计1426个结果
-
BioGene Pharmaceutical Ltd.撤销
-
Vanderbilt-Ingram Cancer CenterBoehringer Ingelheim; National Comprehensive Cancer Network撤销鳞状细胞癌 | 头颈部复发性鳞状细胞癌 | 头部或颈部的转移性鳞状细胞癌
-
University of Kansas Medical Center主动,不招人
-
Jiangsu HengRui Medicine Co., Ltd.主动,不招人
-
Hunan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.未知
-
Affiliated Hospital of North Sichuan Medical CollegeJiangsu HengRui Medicine Co., Ltd.未知
-
Zigong No.1 Peoples HospitalJiangsu HengRui Medicine Co., Ltd.未知
-
Tianjin Medical University Cancer Institute and...招聘中
-
Johns Hopkins UniversityMedical University of South Carolina; Children's Hospital of Philadelphia; Washington University... 和其他合作者完全的
-
Yale UniversityBoehringer Ingelheim招聘中
-
PENTA FoundationRadboud University Medical Center; Baylor College of Medicine; Clinton Health Access Initiative... 和其他合作者尚未招聘
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health...完全的
-
Massachusetts General HospitalBoehringer Ingelheim; Incyte Corporation招聘中
-
Betta Pharmaceuticals Co., Ltd.主动,不招人
-
Cambridge University Hospitals NHS Foundation TrustBoehringer Ingelheim; Cancer Research UK; University of Cambridge; The Brain Tumour Charity终止
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.未知
-
Takeda主动,不招人费城染色体阳性急性淋巴细胞白血病 (Ph+ALL)美国, 中国, 西班牙, 澳大利亚, 加拿大, 阿根廷, 大韩民国, 巴西, 日本, 意大利, 墨西哥, 法国, 希腊, 波兰, 俄罗斯联邦, 奥地利, 台湾, 保加利亚, 芬兰, 火鸡
-
Fifth Affiliated Hospital, Sun Yat-Sen University尚未招聘化疗 | 手术 | 非小细胞肺癌 | EGFR激活突变 | 表皮生长因子受体抑制剂
-
Jiangsu HengRui Medicine Co., Ltd.主动,不招人
-
Peking UniversityPeking University Cancer Hospital & Institute暂停
-
NeuromaxBionevia完全的
-
AZ-VUB未知
-
The Netherlands Cancer InstituteAstraZeneca; Boehringer Ingelheim未知
-
Tianjin Medical University Cancer Institute and...招聘中
-
Peking University Cancer Hospital & Institute招聘中